^
Association details:
| Biomarker: | TP53 wild-type |
|---|---|
| Cancer: | Small Lymphocytic Lymphoma |
| Drug: | Imbruvica (ibrutinib) (BTK inhibitor) + Gazyva (obinutuzumab) (CD20 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Chronic lymphocytic leukemia/Small lymphocytic lymphoma...CLL/SLL without del(17p)/TP53 mutation...First-line therapy…Other recommended regimens…ibrutinib + obinutuzumab (category 2B).
